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Abstract: Multiple conditions result in development of pulmonary hypertension. Pulmonary 
arterial hypertension (PAH) is the subclassification of pulmonary hypertension, in which 
known or unknown underlying conditions lead to similar intrinsic alterations in the pulmonary 
vasculature. PAH is a progressive condition characterized by restricted blood flow through the 
pulmonary circulation leading to poor survival in the absence of effective therapy. Over the last 
two decades, new therapeutic agents have substantially improved the course and   prognosis for 
PAH patients. Three available classes of drugs, ie, prostacyclins, endothelin receptor antagonists, 
and phosphodiesterase-5 inhibitors provide multiple options for treatment of PAH. Endothe-
lin receptor antagonists and phosphodiesterase-5 inhibitors are administered orally, whereas 
prostacyclin therapies are delivered by continuous intravenous or subcutaneous   infusion, or as 
aerosols by nebulization. Because of the risks and inconveniences associated with administra-
tion, prostacyclins are typically reserved for patients with more advanced disease or progression 
despite oral therapy. Inhaled administration may be a safer and easier route for prostacyclin 
administration. Treprostinil is a prostacyclin analog that has been demonstrated to be effective 
when administered by continuous subcutaneous or intravenous infusion, and more recently by 
nebulization.
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Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by 
restricted blood flow through the pulmonary circulation. The current criteria for 
PAH include an elevated mean pulmonary artery pressure greater than 25 mmHg at 
rest, with a pulmonary artery occlusion pressure less than 15 mmHg and pulmonary 
vascular resistance greater than 3 Wood units.1 Elevated pulmonary arterial pressure 
increases the work required of the right ventricle, ultimately leading to right heart 
failure and death. Prior to the development of modern treatments, the one-, three-, and 
five-year survival rates were 68%, 48%, and 34%, respectively.2 With the   development 
of modern therapeutic agents, these survival rates have improved to 86%, 69%, and 
61%, respectively.3
Epidemiology
Pulmonary hypertension is an uncommon disease. Recent registries in the US, 
  Scotland, and France put the overall prevalence of PAH at 15–56 cases per million.4–6 
The recent 2008 World Health Organization (WHO) classification of pulmonary 
  hypertension includes five general categories (Figure 1).7 The previous diagnostic Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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category of primary pulmonary hypertension is now referred 
to as idiopathic PAH, and is included under the classification 
of WHO Class I or PAH. The recently published REVEAL 
study demonstrated that idiopathic PAH is the most prevalent 
form of PAH, accounting for 46.2% of patients.8 Women 
have a 2–3 times greater prevalence of idiopathic PAH in 
most registries. Although previously thought to be a disease 
of young women, the peak prevalence seems to occur in 
the fourth, fifth, and sixth decades of life. Familial forms 
of PAH caused by mutations in bone morphogenic protein 
receptor-2 or activin-like kinase 1 represented only 2.7% of 
cases. Other etiologies of PAH include those associated with 
connective tissue disorders (25.3%), congenital heart disease 
(9.8%), liver disease (5.3%), human immunodeficiency virus 
infection (1.9%), and medication usage, including anorexi-
gens (5.3%). Also included in the PAH classification are 
pulmonary veno-occlusive disease and pulmonary capillary 
hemangiomatosis, which account for less than 0.5% of cases. 
1     Pulmonary arterial hypertension
1.1      Idiopathic
1.2      Heritable
1.2.1       BMPR2
1.2.1       ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3       Unknown
1.3      Drug-induced and toxin-induced
1.4      Associated with
1.4.1       Connective tissue disorder
1.4.2       Human immunodeficiency virus infection
1.4.3       Portal hypertension
1.4.4       Congenital heart diseases
1.4.5       Schistosomiasis
1.4.6       Chronic hemolytic anemia
1.5      Persistent pulmonary hypertension of the newborn
1.6      Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
2     Pulmonary hypertension owing to left heart disease
2.1      Systolic dysfunction
2.2      Diastolic dysfunction
2.3      Valvular disease
3     Pulmonary hypertension owing to lung diseases and/or hypoxemia
3.1      Chronic obstructive pulmonary disease
3.2      Interstitial lung disease
3.3      Other pulmonary diseases with mixed obstructive and restrictive pattern
3.4      Sleep-disordered breathing
3.5      Alveolar hypoventilation disorders
3.6      Chronic exposure to high altitude
3.7      Developmental abnormalities
4     Chronic thromboembolic pulmonary hypertension
5     Pulmonary hypertension with unclear multifactorial mechanisms
5.1      Hematologic disorders, ie, myeloproliferative disorders, splenectomy
5.2      Systemic disorders, ie, sarcoidosis, pulmonary Langerhans cell hystiocytosis,
 lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3      Metabolic disorders, including glycogen storage disease, Gaucher disease,
thyroid disorders
5.4      Others, including tumoral obstruction, fibrosing mediastinitis, chronic renal
            failure on dialysis
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Pulmonary hypertension due to left-sided heart disease, 
hypoxemic lung disease, and thromboembolic disorders are 
each classified separately. Additionally, a miscellaneous 
class includes sarcoidosis, pulmonary Langerhans cell 
  histiocytosis, lymphangiomatosis, fibrosing mediastinitis, 
and other tumors that compress the pulmonary arteries.
While there are many conditions associated with PAH, 
they share common pathophysiologic findings. PAH is a 
vasculopathy involving small arteries in the lung that   regulate 
pulmonary blood flow.9,10 Affected arteries   demonstrate 
intimal hyperplasia, medial hypertrophy, adventitial 
  proliferation, thrombosis in situ, and plexiform   arteriopathy. 
The adventitial proliferation is thought to be due to a 
decreased ratio of apoptosis to proliferation of pulmonary 
artery smooth muscle cells.11 All contribute to narrowing of 
the vessel lumen, leading to increased pulmonary vascular 
resistance.
Endothelial dysfunction further contributes to elevated 
pulmonary artery resistance. Ordinarily, endothelial cells 
produce a balance of vasoconstrictive and vasodilatory 
mediators. In PAH, there is excessive production of endothe-
lin and thromboxane, both of which are vasoconstrictors.12–14 
Similarly, there is a deficit of the vasodilators, prostacyclin 
and nitric oxide.13,15 These molecules have become the targets 
of modern therapeutic interventions for PAH.
Evaluation and diagnosis
The symptoms of PAH are often nonspecific, thus a high 
index of suspicion is required for timely diagnosis. The 
most common symptoms include dyspnea (60%) and fatigue 
(19%).16 Other common symptoms include chest pain (7%), 
syncope (8%), lower extremity edema (3%), and   palpitations 
(5%). Typical signs on physical examination suggest right 
ventricular strain, including an accentuated P2, jugular 
venous distention, a holosystolic tricuspid murmur, and an 
S3 or S4 heart sound. Even with these signs and symptoms, 
there can still be a delay of several years before a definitive 
diagnosis is made.
When PAH is suspected in a patient with appropriate signs 
and symptoms, transthoracic Doppler   echocardiography is the 
most appropriate initial study.9,17 By measuring the   tricuspid 
regurgitant jet, the pulmonary artery systolic pressure can be 
estimated. The sensitivity and specificity for detecting PAH is 
0.79 to 1.00 and 0.68 to 0.98, respectively. When a tricuspid 
regurgitant jet is difficult to visualize, agitated saline can 
be used to enhance its measurement. In studies of normal 
populations, only 5% of individuals have a pulmonary artery 
systolic pressure of greater than 37.9 mmHg, although this 
number increases with advanced age and obesity.18 Thus, 
if pulmonary artery systolic pressure is measured greater 
than 40 mmHg, referral for further evaluation is warranted. 
Echocardiography can also detect other signs of pulmonary 
hypertension, including right ventricular hypertrophy, right 
ventricular enlargement, and impaired right ventricular 
function.
Further testing is directed at evaluating specific   conditions 
associated with PAH and excluding secondary causes of 
pulmonary hypertension.9,10 Chest radiography may reveal 
enlarged pulmonary arteries and right heart structures. 
  Electrocardiogram may demonstrate right ventricular enlarge-
ment and strain pattern. Pulmonary function testing can 
evaluate for significant airflow obstruction or restriction. In the 
appropriate clinical settings, serologic testing for mixed con-
nective tissue disorders, chronic liver disease, human immuno-
deficiency virus infection testing, and screening for obstructive 
sleep apnea and nocturnal hypoxia should be undertaken. 
Ventilation-perfusion scanning and computed tomography 
scanning of the chest assess for chronic thromboembolic 
disease and other pulmonary parenchymal diseases.
The gold standard for diagnosis of PAH is right heart 
catheterization. As first described by Swan and Ganz in 
1970, a catheter is introduced via a central vein through the 
right atrium and right ventricle into the pulmonary artery, 
and direct measurements of pulmonary artery pressures can 
be obtained.19 PAH is defined by a mean pulmonary artery 
pressure greater than 25 mmHg, with a pulmonary artery 
occlusion pressure less than 15 mmHg and a calculated 
pulmonary vascular resistance of greater than 3 Wood units 
(240 dyne-sec/cm5). If the mean pulmonary artery pressure 
is greater than 25 mmHg but the pulmonary artery occlusion 
pressure is greater than 15 mmHg or the pulmonary vascular 
resistance is less than 3 Wood units, then the elevated pres-
sure in the pulmonary arteries is more likely due to elevated 
left atrial pressure resulting from left-sided heart disease. 
These patients are not classified strictly as having pulmonary 
arterial pressure, but rather having WHO Class II pulmonary 
hypertension, and therapeutics are directed at improving left 
ventricular heart function.
Treatment
The goals for pulmonary hypertension treatment focus on the 
reduction of symptoms, enhancement of exercise tolerance, 
normalization of hemodynamic parameters, and improve-
ment of survival. Comprehensive evidence-based guidelines 
for the treatment of PAH have recently been updated.9,10 
These treatments can be divided into general measures Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and agents directed specifically at the pathophysiology of 
PAH. Included in these medications are endothelin receptor 
antagonists, phosphodiesterase inhibitors, and prostacyclin 
analogs, such as treprostinil.
General measures are directed toward minimizing 
hypoxemia and volume overload states that can exacerbate 
PAH. Supplemental oxygen should be provided to keep 
measured oximetry above 90%, with special attention to 
nocturnal hypoxemia and exposure to increased altitude/low 
atmospheric pressure, such as during commercial air travel. 
Influenza and pneumococcal vaccinations are recommended. 
Diuretics and a low sodium diet maintain euvolemia to 
  prevent further right ventricular failure. Pregnancy should 
be avoided due to the volume expansion and increased blood 
flow demands normally experienced during pregnancy. 
In one series, the mortality associated with pregnancy in 
patients with pulmonary hypertension was 30%–56%.20 
Three observational studies suggest that anticoagulation 
should be considered in patients with severe PAH.21–23 One 
short-term study indicated that digoxin may be beneficial in 
patients with low cardiac output.24
Calcium channel blockers may be used in selected 
individuals. During diagnostic right heart catheterization, 
a vasodilator trial with inhaled nitric oxide, intravenous 
  epoprostenol, or adenosine is performed. A positive response 
involves a decrease in mean pulmonary artery pressure 
more than 10 mmHg to a level less than 40 mmHg and no 
decrement in cardiac output. Only about 10% of patients 
meet this criteria, and even fewer have a positive long-term 
response.21,25
Oral agents
Two classes of oral agents are recommended for the treatment 
of mild to moderate PAH (WHO functional class II/III).9,10 
These include the endothelin receptor antagonists, bosen-
tan, ambrisentan, and sitaxsentan, and the phosphodi-
esterase-5 inhibitors, sildenafil and tadalafil.
Endothelin is a 21-amino acid polypeptide first identified 
and isolated from cultured endothelial cells.26,27 Although it is 
produced primarily by endothelial cells, it is also expressed 
in epithelial cells, macrophages, fibroblasts, cardiomyo-
cytes, and other tissues.28 Endothelin secretion occurs both 
in a constitutive fashion and in response to various stimuli, 
  including vascular shear stress, hypoxia, and peptide media-
tors of inflammation. In contrast, nitric oxide, natriuretic 
peptides, and dilator prostanoids inhibit endothelin release. 
Endothelin mediates its biologic effect through two G 
protein-coupled plasma membrane receptors, ET-A and 
ET-B. ET-A is found primarily on vascular smooth muscle 
cells and leads to vasoconstriction, proliferation, and fibrosis. 
ET-B is found in endothelial cells, as well as liver, lung, and 
kidney tissues. Occupancy of endothelial ET-B receptors 
leads primarily to vasodilation and induction of nitric oxide 
and   prostacyclin production. ET-B binding in lung, liver, 
and kidney parenchyma is believed to be one mechanism of 
clearance of endothelin. Patients with pulmonary hypertension 
have increased levels of endothelin, and these levels correlate 
with poorer outcomes.13,29 Thus, antagonism of this peptide 
presents a target for treatment of pulmonary hypertension.
Two endothelin receptor antagonists are currently 
approved by the US Food and Drug Administration for 
treating PAH. Bosentan is an orally available, nonpeptide 
endothelin receptor antagonist that blocks both ET-A and 
ET-B receptors. Ambrisentan is an ET-A specific receptor 
antagonist. Sitaxsentan is another ET-A specific antagonist, 
but is currently not approved for use in the US. The efficacy 
of these medications is the subject of a recent Cochrane 
review.30
Bosentan represents the first endothelin receptor antago-
nist for the treatment of PAH. Channick et al demonstrated 
in 2001 that bosentan given twice daily for at least 12 weeks 
to 32 patients with severe disease led to an improvement 
in six-minute walk distance (6MWD) of 76 meters over 
placebo.31 Additionally, there were improvements in car-
diac output, pulmonary vascular resistance, and reduced 
BORG dyspnea index scores, without a significant num-
ber of adverse events. This was followed by the larger 
BREATHE-1 (  Bosentan Randomized Trial of Endothelin 
Antagonist Therapy) study in 2002, in which 213 patients 
with severe disease received bosentan for at least 12 weeks.32 
Again, patients receiving bosentan had improved 6MWD 
(42 meters), BORG dyspnea index, and WHO functional 
class. Bosentan also increased the time to clinical worsening, 
defined as the combined endpoint of death, lung transplan-
tation, hospitalization for pulmonary hypertension, lack of 
clinical improvement, or worsening, leading to discontinu-
ation, need for epoprostenol therapy, or atrial septostomy. 
Subsequently, several longer-term studies, up to three years in 
duration, have demonstrated a significant survival benefit of 
bosentan compared with historic controls.33,34 Patients taking 
bosentan had survival rates of 92%, 89%, and 79% at years 
1, 2, and 3, respectively, compared with expected survival of 
71%, 61%, and 51%. In 2008, Galie et al demonstrated that 
bosentan benefited patients with milder, WHO functional 
class II disease.35 These studies demonstrated the most com-
mon adverse effect was an elevation in hepatic enzymes that Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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was thought to be due to ET-B receptor antagonism leading 
to decreased clearance. This led to the development of the 
ET-A specific agents, sitaxsentan and ambrisentan.
Sitaxsentan was the first ET-A specific receptor antago-
nist for the treatment of PAH. It has about 6500 times 
greater affinity for ET-A than for ET-B receptors.36 The 
STRIDE-1 (Sitaxsentan To Relieve Impaired Exercise) 
study examined the safety and efficacy of sitaxsentan in 
118 patients over a 12-week period.37 Although a secondary 
endpoint, there was an improvement in 6MWD of 35 and 
33 meters with daily administration of 100 mg and 300 mg 
of sitaxsentan, respectively. However, elevations in hepatic 
aminotransferases were observed in 10% of the 300 mg group 
  compared with 3% for the placebo arm. The STRIDE-2 study 
examined the effects of lower doses of sitaxsentan, from 
50 mg to 100 mg.38 Again, improvements in 6MWD of 24.2 
and 31.4 meters were seen for 50 mg and 100 mg doses, 
  respectively. The rates of elevated hepatic aminotransferases 
were similar to placebo (3%–5% versus 6%). An extension 
of the STRIDE-1 in 11 patients for one year demonstrated 
that 100 mg of   sitaxsentan daily led to a sustained improve-
ment in 6MWD of 50 meters, improved functional class, 
and hemodynamics compared with baseline.39 There were 
no reports of hepatotoxicity in this study.
Ambrisentan is an oral, nonsulfonamide ET-A selective 
receptor antagonist with a half-life of 9–15 hours, allowing 
once-daily dosing. The safety and efficacy of ambrisentan 
was first shown in 2005.40 In 64 patients with PAH, daily 
administration of ambrisentan led to an improvement of 
6MWD of 36.1 meters, improved dyspnea, WHO functional 
class, and cardiopulmonary hemodynamics. Subsequently, 
the larger ARIES-1 and 2 studies demonstrated improved 
6MWD, dyspnea scores, and time to clinical worsening in 
202 and 192 patients, respectively.41 Neither of these studies 
showed an elevation in liver enzymes greater than three times 
the upper limit of normal. However, peripheral edema was 
observed to a greater extent in patients taking ambrisentan. 
An extension of the ARIES study showed improved 6MWD 
in 280 patients after 48 weeks of treatment.
The phosphodiesterase inhibitors, sildenafil and tadalafil, 
represent the second class of oral agents for the treatment 
of PAH. In the lung, nitric oxide acts as an important vaso-
dilator via stimulation of cyclic guanidine monophosphate 
(cGMP) synthesis. Cyclic GMP activates protein kinase G, 
which mediates lower intracellular calcium in vascular 
smooth muscle and facilitates vascular relaxation, antipro-
liferation, and apoptosis.42 Phosphodiesterase-5 hydrolyzes 
cGMP, which prevents protein kinase G activation and its 
downstream effects. In PAH, there is increased expression 
of phosphodiesterase-5 in the lung and decreased expression 
of nitric oxide synthase.43,44 Both the reduction in cGMP 
production and its increased hydrolysis lead to pulmonary 
smooth muscle vasoconstriction and proliferation. Antago-
nism of phosphodiesterase-5 with either sildenafil or tadalafil 
increases cGMP levels, leading to relaxation of pulmonary 
vascular smooth muscle and decreased pulmonary vascular 
resistance.
The safety and efficacy of sildenafil for the treatment 
of PAH was demonstrated in the SUPER (Sildenafil Use 
in   Pulmonary Arterial Hypertension) trial.45 Published in 
2005, this was a double-blind, placebo-controlled study of 
278 patients with symptomatic PAH sponsored by Pfizer. 
During 12 weeks of treatment with 20 mg, 40 mg, or 80 mg 
three times daily, sildenafil treatment led to improvements in 
6MWD of 45, 46, and 50 meters, respectively. At all doses, 
mean pulmonary artery pressure was decreased and WHO 
functional class was improved. A follow-up study of 
222 patients who continued to take 80 mg of sildenafil showed 
an improved 6MWD of 51 meters after one year of treatment. 
Additionally, health-related quality of life measurements also 
improved with sildenafil treatment at 24 weeks.46
Tadalafil is a once-daily dosed selective inhibitor of phos-
phodiesterase-5. Previously approved for erectile dysfunc-
tion, the utility of tadalafil in PAH was demonstrated by the 
PHIRST (Pulmonary Arterial Hypertension and Response to 
Tadalafil) study.47 In this 16-week, double-blind, randomized, 
placebo-controlled study sponsored by Eli Lilly, 405 patients 
received varied doses of tadalafil or placebo. Tadalafil lead 
to improvements in 6MWD in a dose-dependent fashion. 
Although there was no improvement in WHO functional 
class, the time to clinical worsening was longer with tadalafil 
40 mg daily. At the highest doses, tadalafil treatment also 
improved cardiac output and reduced pulmonary vascular 
resistance.
Prostacyclin analogs
Prostacyclin is an endogenous vasodilator produced by 
prostacyclin synthase in endothelial cells of the pulmonary 
vasculature. Prostacyclin acts locally to promote vasodilation 
and reduce pulmonary vascular resistance. In PAH, there is 
imbalance between this vasodilator and other vasoconstri-
ctor molecules, with decreased expression of prostacyclin 
synthase and increased levels of thromboxane A2.12,15 In addi-
tion to vasodilation, prostacyclin has an antiproliferative 
effect on smooth muscle cells in vitro.48 Abnormal levels of 
prostacyclin facilitate the medial hypertrophy seen in PAH. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Furthermore, prostacyclin prevents platelet activation 
and aggregation by thromboxane A2.49 Reduced levels of 
prostacyclin allow for thrombosis in situ also seen in PAH. 
Thus, pharmacologic restoration of prostacyclin levels would 
prevent the vasoconstriction, smooth muscle cell prolifera-
tion, thrombosis in situ, and plexiform arteriopathy that are 
hallmarks of PAH.
Three prostacyclin analogs are approved for the treat-
ment of PAH in the US, ie, epoprostenol, treprostinil, and 
iloprost (Figure 2). Beraprost is not currently approved by 
the Food and Drug Administration. Epoprostenol was the 
first prostacyclin approved for the treatment of PAH. Due 
to its short half life (,six minutes) and poor stability at 
pH , 10.5,   epoprostenol must be refrigerated for storage 
and administered as a continuous infusion through a central 
venous catheter. These limitations led to the development of 
the tricyclic benzidine prostacyclin, treprostinil.   Treprostinil 
may be given either as a continuous intravenous or subcuta-
neous infusion with similar bioavailability.50 The half-life of 
treprostinil is 4.4 and 4.6 hours by intravenous and subcuta-
neous infusion, respectively. More recently, an inhaled form 
has become available with four times daily dosing. Iloprost 
also may be inhaled, as often as 6–9 times per day due to its 
short half-life (20–30 minutes).
Three seminal studies have demonstrated the clinical 
effectiveness of epoprostenol for PAH.51–53 In 81 patients 
with functional class III/IV primary pulmonary hyperten-
sion, Barst et al demonstrated that epoprostenol infusion 
improved 6MWD, mean pulmonary artery pressure, 
  pulmonary   vascular resistance, and survival. However, four 
episodes of catheter-related sepsis and one thrombotic event 
were noted.53 Subsequently, McLaughlin et al demonstrated 
that epoprostenol therapy not only improved hemody-
namic   parameters, but also improved survival over a mean 
36.1-month follow-up period in 162 patients compared with 
  historic controls.51 Sitbon et al similarly demonstrated a 
survival   benefit of intravenous epoprostenol therapy in a 
separate study of 178 patients with moderate to severe PAH.52 
Badesch et al extended the utility of epoprostenol beyond 
patients with primary pulmonary hypertension in 2000. In 
111 patients with pulmonary hypertension due to scleroderma, 
epoprostenol improved pulmonary   vascular hemodynamics 
and exercise capacity over a 12-week treatment course.54 In 
addition, nonrandomized studies have suggested that epopros-
tenol treatment may be effective in patients with PAH due to 
congenital   left-to-right shunts, portopulmonary hypertension, 
and human immunodeficiency virus infection.55–58
The pharmacodynamics of treprostinil were recently 
reviewed in this journal.59 Unlike epoprostenol, treprostinil 
is chemically stable at room temperature and at neutral pH. 
This facilitates its use in both intravenous and subcutane-
ous   infusion. Simonneau et al evaluated the efficacy of 
continuous subcutaneous treprostinil in 470 patients over 
a 12-week period.60 In this study, 6MWD improved in a 
dose-dependent fashion, as did dyspnea indices and hemody-
namics. Infusion site pain and reactions were common, com-
plicating therapy in 85% and 83% of patients,   respectively. 
The effects of long-term subcutaneous treprostinil were 
separately examined in 99 patients with PAH and 23 patients 
with chronic thromboembolic pulmonary hypertension.61 
After a mean follow-up of 26.2 months, patients treated with 
subcutaneous treprostinil demonstrated increased 6MWD 
as well as improved dyspnea score, functional class, and 
overall survival. Barst et al followed 806 patients for up to 
four years on subcutaneous treprostinil therapy and demon-
strated improved survival   versus historic controls.62 Of the 
196 patients who discontinued the medication, 34% stopped 
within the first year of treatment due to infusion site pain. 
Intravenous treprostinil therapy was studied in a 12-week, 
open-label study in 16 patients with PAH.63 Continuous intra-
venous treprostinil improved 6MWD (82 meters compared 
with baseline), hemodynamics, and BORG dyspnea score.
Iloprost is an inhaled carbacyclin prostacyclin analog used 
to treat pulmonary hypertension.64 Early studies comparing 
inhaled epoprostenol and iloprost demonstrated short-term 
efficacy of both agents, but iloprost had a significantly longer 
duration of action (10–30 minutes versus 60–120 minutes).65 
In an uncontrolled trial, Olschewksi et al demonstrated 
the benefit of inhaled iloprost nebulized 6–12 times daily 
over the course of three months.66 A large, randomized 
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controlled study of iloprost confirmed this benefit.67 Over 
a period of 12 weeks, patients treated with inhaled iloprost 
six or nine times daily demonstrated increased 6MWD 
(36.4 meters), improved hemodynamics, and functional 
class. In this study, syncope, flushing, and cough significantly 
increased with inhaled iloprost. The long-term efficacy of 
inhaled iloprost was studied in 24 patients over the course 
of one year.68 Patients had a sustained improvement in 
6MWD, cardiac output, and pulmonary vascular resistance. 
However, in a separate study, after 12 months, only 32 of 
76 patients were stabilized on iloprost monotherapy, most 
requiring additional therapy (23 patients) or transplant (two 
patients).69
Beraprost is a stable, cyclopentabenzofuranyl prostacyclin 
analog that enables oral administration. ALPHABET (  Arterial 
Pulmonary Hypertension and Beraprost European Trial) was 
a randomized, placebo-controlled study of 130 patients with 
PAH over 12 weeks.70 Beraprost administered at a dose of 
up to 120 µg four times daily improved exercise capacity in 
patients with idiopathic PAH although it did not significantly 
alter the hemodynamic outcomes measured. Headache, flush-
ing, jaw pain, diarrhea, and nausea were frequent during the 
titration period but were less common in the maintenance 
phase. In contrast, Barst et al failed to demonstrate sustained 
improvement in exercise tolerance or disease progression in 
116 patients with WHO functional class II or III PAH due 
to collagen vascular disease or congenital heart disease.71 
A retrospective study of 58 patients with idiopathic PAH 
demonstrated a three-year survival rate of 76% compared 
with 44% with conventional therapy.72 Beraprost is currently 
approved for treatment of PAH in Japan.
Inhaled treprostinil
The difficulty with injection site pain and potential pharma-
cologic benefits of inhaled therapy led to the development 
of aerosolized treprostinil therapy for PAH. Initial inves-
tigations compared the effects of inhaled and intravenous 
treprostinil in sheep with PAH induced by 9,11-dideoxy-9, 
11-epoxymethanoprostaglandin F2 (U44069), a PGH2 ana-
log that led to a four-fold increase in pulmonary vascular 
  resistance.73 Both inhaled and intravenous treprostinil 
reversed this effect in a dose-dependent fashion. However, 
only inhaled treprostinil at 1000 ng/kg/min fully reversed the 
pulmonary arterial vasoconstriction and normalized pulmo-
nary artery pressures. At this dose, there was no significant 
change in systemic blood pressure, cardiac output, or heart 
rate. The duration of effect of inhaled treprostinil was about 
three times greater than that of inhaled epoprostenol, thereby 
demonstrating the efficacy of inhaled treprostinil in an animal 
model of PAH.
The first published trial of inhaled treprostinil in humans 
characterized its effects in three patients with severe PAH.74 
After right heart catheterization, each patient received a 
single administration of 15 µg of treprostinil in three breaths 
through an ultrasonic inhalation device. This single dose 
reduced pulmonary vascular resistance by 45.2% ± 17.5%, 
with sustained effects observed for longer than 180 minutes 
after inhalation. Subsequently, two patients continued on 
inhaled treprostinil therapy, 15 µg four times daily, on a 
compassionate treatment basis. After three months, both had 
improvement in functional class and 6MWD.
Further studies in humans compared inhaled treprostinil 
with iloprost. Voswinckel et al compared the effects of 
these medications in 123 patients with different forms of 
PAH.75 Administration of either medication led to a rapid 
decrease in pulmonary vascular resistance and pulmonary 
artery pressure. A comparison of three inhaled treprostinil 
regimens, ie, 7.5 µg over six minutes, 15 µg over six   minutes, 
or 15 µg over three minutes, showed no significant differ-
ence in pulmonary vascular resistance reduction. When 
compared with iloprost, the maximum effect of inhaled 
treprostinil was comparable. However, the peak effect of 
iloprost (8 ± 1 minutes) was observed more quickly than 
for inhaled treprostinil (18 ± 2 minutes), while the inhaled 
treprostinil led to a more prolonged effect extending beyond 
the three-hour experimental window. Peak plasma trepro-
stinil levels were observed 10–15 minutes after inhalation, 
consistent with the drug’s peak effect. In this small study, 
the most common side effects of treprostinil were cough 
(six of 48 patients), headache (two of 48 patients), and jaw 
pain (1 of 48 patients).
Additional clinical trials have been performed to evalu-
ate the combination of inhaled treprostinil with other PAH 
therapies. In a 12-week, open-label safety and efficacy trial, 
12 patients with PAH and functional class III or IV symptoms 
despite oral bosentan administration received additional 
inhaled treprostinil.76 Two dosing regimens were used, ie, 
30 µg (six inhalations) four times daily and 45 µg (nine inha-
lations) four times daily, via a hand-held ultrasonic, single-
breath nebulizer. Acutely, the effect of inhaled treprostinil 
peaked at 45 minutes and returned to baseline by 180 minutes. 
After 12 weeks of therapy, significant reductions in mean 
pulmonary artery pressure and pulmonary vascular resistance 
were observed at peak post-inhalation, with a trend toward Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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improvement in cardiac output. Notably, both pre- and 
post-inhalation 6MWD was improved with therapy.
The acute effects of the combination of sildenafil and 
inhaled treprostinil have also been studied.77 Fifty patients 
with moderate to severe pulmonary hypertension received 
sildenafil plus 15 µg or 30 µg inhaled treprostinil. Inhaled 
treprostinil induced a significant reduction in pulmonary 
vascular resistance and pulmonary arterial pressure beyond 
the treatment effect from sildenafil alone that was present up 
to two hours after inhalation. While the 15 µg and 30 µg doses 
were equally effective, the 30 µg dose had a longer duration 
of action. Interestingly, a subgroup analysis of patients with 
either PAH or chronic thromboembolic pulmonary hyper-
tension demonstrated similar results. Approximately 10% 
of patients reported a cough, but the known side effects of 
sildenafil including headache, musculoskeletal pain, dizzi-
ness, and hypotension, were not potentiated by treprostinil 
inhalation. Also, ventilation/perfusion matching was not 
significantly altered by treprostinil administration.
Recently, a metered dose inhaler (MDI) formulation of 
treprostinil was evaluated.78 This device has the advantages 
of a smaller size and improved ease of use compared with the 
ultrasonic nebulizer. The aerodynamic aerosol diameter of 
MDI treprostinil is 4–5 µm, which is at the upper size limit 
for alveolar deposition. Doses of 30 µg, 45 µg, or 60 µg of 
MDI treprostinil lowered mean pulmonary artery pressure 
and pulmonary vascular resistance. Pulmonary vasodila-
tion extended beyond the observation period of two hours. 
  Pulmonary vascular resistance reduction by MDI was 
comparable with that previously observed with ultrasonic 
nebulizer. There was no observed decrease in ventilation/
perfusion matching by treprostinil delivered by MDI.
Currently, treprostinil is delivered using an ultrasonic 
pulse-delivery nebulizer system.79 Initial dosing begins at 
three breaths or 18 µg four times daily, and may be increased 
at 1–2-week intervals up to a maximum dose of nine breaths 
(54 µg) four times daily. Cough, headache, throat irritation, 
nausea, and flushing are common side effects of inhaled 
treprostinil.
Conclusion
The number of available treatments for PAH continues to 
increase. Three classes of drugs, ie, prostacyclins,   endothelin 
receptor antagonists, and phosphodiesterase-5 inhibitors, 
affecting different mechanisms involved in the pathogen-
esis of PAH, are currently available. Endothelin recep-
tor antagonists and phosphodiesterase-5 inhibitors are 
administered orally at a frequency that varies from once to 
three times daily. Prostacyclin therapies are delivered by 
continuous intravenous infusion (epoprostenol and trepros-
tinil), by continuous subcutaneous infusion (treprostinil), or as 
aerosols by nebulization (iloprost and treprostinil).   Typically, 
oral therapies are utilized for patients with milder disease, 
whereas the prostacyclins are initiated in patients with more 
advanced disease, or progression despite oral therapy. The 
use of inhaled agents reduces the risks and inconveniences 
associated with infused treatments, and further expand the 
potential role for prostacyclin therapies. Continued experi-
ence and evaluation of inhaled treprostinil, particularly in 
combination with oral therapies, will help to provide further 
assessment of its long-term safety and efficacy.
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